New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
08:30 EDTBAYRYFDA says data doesn't support aspirin as defense against first heart attack
The FDA stated in a consumer information communication issued May 2 that it has reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. "In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established," the FDA said. The available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have cardiovascular disease or who have already had a heart attack or stroke, the FDA added, stating that the known benefits of aspirin for secondary prevention outweigh the risk of bleeding in patients who have had a cardiovascular event. “Importantly, the ruling does not impact the numerous cardiovascular indications for which aspirin is already approved by the FDA,” Anne Coiley, a spokeswoman for Bayer, said in an e-mail to Bloomberg. Reference Link
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
13:37 EDTBAYRYPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
October 20, 2014
07:11 EDTBAYRYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 14, 2014
14:03 EDTBAYRYCompugen achieves second preclinical milestone under Bayer cancer collaboration
Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use